ERNI MODIFIES THE EFFECT OF GLUTAMINE DEPRIVATION ON TUMOR GROWTH RELATED FACTORS EXPRESSION IN U87 GLIOMA CELLS

O. H. MINCHENKO, A. P. KHARKOVA, O. S. HNATIUK,
O. Y. LUZINA, I. V. KRYVDIUK, A. Y. KUZNETSOVA

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: ominchenko@yahoo.com

The expression of a subset of genes encoding important tumor growth related factors in U87 glioma cells with ERN1 (endoplasmic reticulum to nucleus signaling 1) loss of function as well as upon glutamine deprivation was studied. It was shown that glutamine deprivation down-regulated the expression level of ATF6 (activating transcription factor 6), EIF2AK3/PERK (eukaryotic translation initiation factor 2 alpha kinase 3), GLOI (glyoxalase I), BIRC5 (baculoviral IAP repeat-containing 5), and RAB5C (RAB5C, a member of RAS oncogene family) mRNAs in control glioma cells. At the same time, the expression level of HSPB8 (heat shock 22kDa protein 8) and HSPA5/GRP78 (heat shock protein family A (Hsp70) member 5) mRNAs was resistant to glutamine withdrawal in these glioma cells. It was also shown that inhibition of ERN1, which controlled cell proliferation and tumor growth, modified the effect of glutamine deprivation on the expression levels of most studied genes in U87 glioma cells: up-regulated the expression of ATF6 and HSPA5 genes and enhanced sensitivity of EIF2AK3 and BIRC5 genes to glutamine withdrawal. Furthermore, the expression of all studied genes, except EIF2AK3, was down-regulated in ERN1 knockdown glioma cells in the presence of glutamine. It was demonstrated that glutamine deprivation affected the expression of most studied genes in ERN1 dependent manner and that these changes possibly contributed to the suppression of glioma growth from cells without ERN1 signaling enzyme function.

Key words: glutamine deprivation, ERN1 inhibition, mRNA expression, ATF6, EIF2AK3, BIRC5, RAB5C, HSPA5, U87 glioma cells.

The endoplasmic reticulum stress is an important component of tumor growth, including glioblastoma multiforme, which is highly aggressive tumor with very poor prognosis and to date there is no efficient treatment available [1-5]. Its aggressiveness is due to increased invasion, migration, proliferation, angiogenesis, and a decreased apoptosis [6]. Diffuse infiltrating gliomas are the most common tumors of the central nervous system. ERN1/IRE1 (endoplasmic reticulum to nucleus signaling 1/inositol requiring enzyme 1) signaling pathway of endoplasmic reticulum stress is a central mediator of the unfolded protein response and inhibition of this signaling pathway leads to a suppression of glioma growth through down-regulation of proliferation processes as a result of metabolic reprogramming of cancer cells [7-10]. The endoplasmic reticulum stress controls the expression of numerous regulatory and proliferation related genes, which are responsible for glioblastoma progression [8, 10-14].

It is well known that glutamine is an important factor of glioma development and a more aggressive behaviour [15, 16]. Furthermore, tumor cells have high-energetic and anabolic needs and are known to adapt their metabolism to be able to survive and support proliferation under conditions of nutrient stress. Recently, Polet et al. [17] found that glutamine withdrawal inhibited leukemia cell growth but also led to a glucose-independent adaptation maintaining cell survival through the up-regulation of two important enzymes of the serine pathway: phosphoglycerate dehydrogenase (PHGDH) and phosphoserine ami-
notransferase (PSAT1). Furthermore, serine is a key pro-survival actor that needs to be handled to sensitize leukemia cells to glutamine-targeting modalities, because it contributed to cell regrowth following glutamine deprivation [17]. It is interesting to note that protein kinase C epsilon (PRKCE) is a critical metabolic tumor suppressor and its deficiency promotes the plasticity, which is necessary for tumor cells to reprogram their metabolism: utilize glutamine through the serine biosynthetic pathway in the absence of glucose [18]. PRKCE is a calcium-independent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cell adhesion, motility, migration and cell cycle and is involved in immune response, cancer cell invasion and regulation of apoptosis. Thus, a better knowledge of tumor responses to glutamine deprivation condition is required to elaborate therapeutical strategies of cell sensibilization, based on the blockade of survival mechanisms.

Previously was shown that glutamine withdrawal affected the expression of several tumor growth related genes and that the effect of glutamine deprivation on most of these genes expression is dependent on ERN1 signaling enzyme function [19-23]. However, the regulation of the expression of many other tumor growth related genes by glutamine deprivation in relation to inhibition of ERN1 to not to be clarified yet. Among them ATF6 (activating transcription factor 6) gene encoding an important transcription factor, which participate in the endoplasmic reticulum stress signaling and controls the transcription of numerous stress responsible genes [24, 25]. Furthermore, ATF6 activates stress responsible gene expressions and regulates cellular senescence, which is known as an anti-tumor barrier [5, 26]. Eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), which also known as PKR-like ER kinase (PERK), is an eIF2alpha kinase that inhibits protein translation and is involved in control of cell proliferation and tumorigenesis, in mitochondrial function and apoptosis [27-29]. It is also an important signaling protein of endoplasmic reticulum stress signaling pathways [5].

Glyoxalase 1 (GLO1) is responsible for the formation of S-lactoyl-glutathione from methylglyoxal, a dicarbonyl compound that is produced as a side product during glycolysis and induces the formation of advanced glycation end-products, which are implicated in several pathologies including cancer [30]. Thus, this enzyme is implicated in the progression of human malignancies and is up-regulated in tumor tissues with high metabolic rate [31]. At the same time, there is data that the activity of GLO1 in high stage colorectal cancer is lower compared to low stage ones [32]. Furthermore, knockdown of GLO1 in the cancer cells significantly reduced tumor-associated properties such as migration and proliferation, whereas hypoxia caused inhibition of cell growth of all cells except of those over-expressing GLO1 [33]. There is data that this enzyme drives epithelial-to-mesenchymal transition and is responsible for cell transformation into a neoplastic-like phenotype [34]. The heat shock protein family A (Hsp70) member 5 (HSPA5), also known as 78 kDa glucose regulated protein (GRP78) and immunoglobulin heavy chain-binding protein (BiP) protein as well as the heat shock 22 kDa protein 8 (HSPB8), also known as protein kinase H11 (H11) and small stress protein-like protein HSP22, plays an important role in tumorigenesis [35-39].

The baculoviral IAP repeat-containing 5 (BIRC5), also known as apoptosis inhibitor 4 (API4) and survivin variant 3 alpha, is overexpressed in most tumors and has dual roles in promoting cell proliferation and preventing apoptosis, in cell cycle regulation [40]. Oncogene RAB5C is a member of RAS oncogene family and its overexpression in pancreatic cancer is associated with cancer progression [41]. There is also data that RAB5C is a target of miR-509 and an important regulator of precursor-B acute lymphoblastic leukemia cell growth because co-expression of the RAB5C open reading frame without its 3′ untranslated region blocked the growth-inhibitory effect mediated by miR-509 [42].

The aim of this study was investigation the effect of glutamine deprivation on the expression level of ATF6, EIF2AK3, GLO1, HSPB8, HSPA5, BIRC5, and RAB5C genes in U87 glioma cells on a relation to ERN1 inhibition with hopes of elucidating its mechanistic part in the glioblastoma growth through endoplasmic reticulum stress signaling.

Materials and Methods

Cell Lines and Culture Conditions. In this study we used two sublines of U87 glioma cells, which are growing in high glucose (4.5 g/l) Dulbecco’s modified Eagle’s minimum essential medium (DMEM; Gibco, Invitrogen, USA) supplemented with glutamine (2 mM), 10% fetal bovine serum (Equitech-Bio, Inc., USA), streptomycin (0.1 mg/ml; Gibco) and penicillin (100 units/ml; Gibco) at 37 °C.
in a 5% CO$_2$ incubator. One subline was obtained by selection of stable transfected clones with overexpression of vector (pcDNA3.1), which was used for creation of dominant-negative constructs (dnERN1). This untreated subline of glioma cells (control glioma cells) was used as control 1 in the study of effects of glutamine deprivation on the expression level of ATF6, EIF2AK3, GLO1, BIRC5, RAB5C, HSPB8, HSPA5, BIRC5, and RAB5C genes. Second subline was obtained by selection of stable transfected clones with overexpression of dnERN1 and has suppressed both protein kinase and endoribonuclease activities of this bifunctional sensing and signaling enzyme of endoplasmic reticulum stress. The expression level of studied nuclear genes encoded mitochondrial proteins in these cells was compared with cells, transfected by vector (control 1). The subline, which overexpress dnERN1, was also used as control 2 for investigation the effect of glutamine deprivation condition on the expression level of studied in cells with inhibited signaling enzyme ERN1 function. Clones were received by selection at 0.8 mg/ml geneticin (G418) and grown in the presence of this antibiotic at lower concentration (0.4 mg/ml).

Glutamine deprivation condition were created by changing the complete DMEM medium into culture plates on the medium without glutamine (from Gibco) and plates were exposed to this condition for 16 h. The suppression level of ERN1 both enzymatic activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level was estimated previously [12, 13] by determining the activity in glioma cells that overexpress a dominant-negative construct of inositol requiring enzyme-1 was estimated previously [12, 13] by determining the phosphorylation of ERN1 and the expression level...
family (RAB5C) was performed using forward primer (5′–GAGTCTGCGGTAGGCAAATC–3′) and reverse primer (5′–CCCGTGCAAATGTATCCTGTG–3′). These oligonucleotides correspond to sequences 285–304 and 534–515 of human RAB5C cDNA (GenBank accession number NM_004583). The size of amplified fragment is 250 bp. The amplification of the baculoviral IAP repeat-containing 5 (BIRC5), also known as apoptosis inhibitor 4 (API4) and survivin variant 3 alpha, cDNA was performed using forward primer (5′–GGACCACCGCATCTCTACAT–3′) and reverse primer (5′–GACAGAAAGGAAAGCGCAAC–3′). These oligonucleotides correspond to sequences 166–185 and 388–369 of human BIRC5 cDNA (GenBank accession number NM_001168). The size of amplified fragment is 204 bp. For amplification of the heat shock protein family A (Hsp70) member 5 (HSPA5), also known as 78 kDa glucose-regulated protein (GRP78) and immunoglobulin heavy chain-binding protein (BIP), cDNA we used next primers: forward 5′–GCTGCGAGAATGAAGCTCTC–3′ and reverse 5′–ATCAAGACGGTTCCCCTTCAGG–3′. The nucleotide sequences of these primers correspond to sequences 253–272 and 488–469 of human HSPA5 cDNA (GenBank accession number NM_005347). The size of amplified fragment is 236 bp. The amplification of the beta-actin (ACTB) cDNA was performed using forward 5′–GGACTTCGAGCAAGAGATGG–3′ and reverse 5′–AGCACTGTGTTGGCGTACAG–3′ primers. These primers nucleotide sequences correspond to 747–766 and 980–961 of human ACTB cDNA (GenBank accession number NM_001101). The size of amplified fragment is 234 bp.

The expression of β-actin mRNA was used as control of analyzed RNA quantity. The primers were received from Sigma-Aldrich (St. Louis, MO, USA). The quality of amplification products was analyzed by melting curves and by electrophoresis using 2% agarose gel. An analysis of quantitative PCR was performed using special computer program “Differential Expression Calculator”. The values of ATF6, EIF2AK3, GLO1, BIRC5, RAB5C, HSPB8, and HSPA5 proteins, which are related to the regulation of tumor growth, in two sublines of U87 glioma cells in relation to inhibition of ERN1 signaling enzyme. It was shown that glutamine deprivation lead to small, but statistical significant, down-regulation of the expression of ATF6 gene (-14% as compared to control 1) in control glioma cells (transfected by empty vector) Fig. 1). However, inhibition of ERN1, a major signaling pathway of the unfolded protein response, significantly down-regulates the expression of ATF6 gene in the presence of glutamine (-42% as compared to control 1, but strongly increases the

**Results and Discussion**

We have studied the effect of glutamine withdrawal on the expression of genes encoding ATF6, EIF2AK3, GLO1, BIRC5, RAB5C, HSPB8, and HSPA5 proteins, which are related to the regulation of tumor growth, in two sublines of U87 glioma cells in relation to inhibition of ERN1 signaling enzyme. It was shown that glutamine deprivation lead to small, but statistical significant, down-regulation of the expression of ATF6 gene (-14% as compared to control 1) in control glioma cells (transfected by empty vector) Fig. 1). However, inhibition of ERN1, a major signaling pathway of the unfolded protein response, significantly down-regulates the expression of ATF6 gene in the presence of glutamine (-42% as compared to control 1, but strongly increases the

---

**Fig. 1. Effect of glutamine deprivation on the expression level of ATF6 (activating transcription factor 6) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 (dnERN1). Values of ATF6 mRNA expressions were normalized to β-actin mRNA level and represented as percent for control 1 (100%); n = 4**
sensitivity of \textit{ATF6} gene expression to glutamine deprivation condition as well as modifies the direction of changes (+184% as compared to control 2; Fig. 1).

As shown in Fig. 2, the expression level of \textit{EIF2AK3/PERK} gene is also slightly but statistically significant down-regulated (-13%) in control glioma cells. However, the suppression of ERN1 signaling enzyme function significantly enhances the sensitivity of this gene expression to glutamine withdrawal in glioma cells: the level of \textit{EIF2AK3} gene is decreased more than in two fold in comparison to control 2. At the same time, the expression of this gene is resistant to the inhibition of ERN1 signaling enzyme in glioma cells growing with glutamine (Fig. 2).

Next, we have shown that glutamine deprivation down-regulated the expression of \textit{GLO1} gene both in control as well as ERN1 knockdown glioma cells: -36 and -31%, correspondingly (Fig. 3). Thus, inhibition of ERN1 did not significantly change the effect of glutamine withdrawal on the expression of \textit{GLO1} gene. Furthermore, inhibition of ERN1, a major signaling pathway of the unfolded protein response, strongly down-regulates the expression of \textit{GLO1} gene in glioma cells growing with glutamine (-91% as compared to control 1; Fig. 3).

As shown in Fig. 4 and 5, glutamine deprivation down-regulates the expression of genes for \textit{BIRC5} and \textit{RAB5C} (both -24%) in control U87 glioma cells, but inhibition of ERN1 signaling enzyme function
in glioma cells by dnERN1 eliminates effect of glutamine withdrawal on the expression of RAB5C gene and enhances the sensitivity of BIRC5 gene expression to this condition.

Furthermore, inhibition of ERN1 leads to significant down-regulation of BIRC5 and RAB5C mRNA expressions in glioma cells growing with glutamine: -40% for BIRC5 gene and -77% for RAB5C gene (Fig. 4 and 5). Thus, these results clearly demonstrated that glutamine deprivation has similar suppressive effect on the expression level of BIRC5 and RAB5C genes in control U87 glioma cells and that inhibition of ERN1 signaling enzyme function by dnERN1 modifies the effect of glutamine withdrawal on the expression of both these genes.

Next, we have studied the effect of glutamine deprivation on the expression of HSPB8 and HSPA5 genes in control as well as in ERN1 knockout glioma cells (Fig. 6 and 7). It was shown that glutamine withdrawal did not significantly change the expression of both genes, but inhibition of ERN1 introduces sensitivity of HSPA5 gene expression to glutamine deprivation (Fig. 7). At the same time, inhibition of ERN1 signaling did not significantly affect the expression of HSPB8 gene in glioma cells. As shown in Fig. 6 and 7, inhibition of ERN1 in glioma cells growing with glutamine significantly reduces the expression of HSPA5 gene (-26% as compared to control 1) and strongly down-regulated HSPB8 gene expression (-86% as compared to control 1).

Thus, we have shown that inhibition of ERN1 signaling significantly reduces the expression of most studied genes, which encoded proteins with pro-proliferative properties. It is possible that expression of these genes is regulated by XBP1 transcription factor, activated by ERN1 [7, 10, 12, 44].
Bioinformatics analysis of the presence of XBPI-responsive motif (CCACG-box) in the promoter region of BIRC5, RAB5C, EIF2AK3, HSPA5, ATF6, HSPB8, and GLO1 genes showed that most of these genes have one or several potential XBPI binding sites preferentially upstream of the transcription start site (Table). At the same time, we did not identify XBPI binding sites in the promoter region of GLO1 and HSPB8 genes. It is possible that ERN1 mediated regulation of these genes expression is mediated through protein kinase of ERN1 like epiregulin and some other genes [7, 13].

Summarized effect of glutamine deprivation on the expression of genes encoding important proliferation related regulatory factors, such as ATF6, EIF2AK3/PERK, GLO1, BIRC5/survivin, RAB5C, HSPB8/H11, and HSPA5/BiP/GRP78, in the control and ERN1 knockdown glioma cells is represented in Fig. 8. Glutamine withdrawal down-regulated the expression of most studied factors and these results completely agree with functional activity of ATF6, EIF2AK3/PERK, GLO1, BIRC5/survivin, and RAB5C proteins, which shown pro-proliferative effects [16-18, 24-32].

ATF6 and EIF2AK3 are important signaling proteins of endoplasmic reticulum stress signaling pathways [5]. The functional activity of these signaling proteins is increased in malignant tumors possibly through the regulation of glutaminase expression by the oncogenic transcription factor c-Jun [45]. Thus, glutamine withdrawal leads to down-regulation of ATF6 and EIF2AK3 gene expressions...
**Matches for XBPI CCACG-box (XBPI-responsive motif) in the promoter region of BIRC5, RAB5C, EIF2AK3, HSPA5, ATF6, HSPB8, and GLO1 genes**

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Position relative to the transcription start site</th>
<th>Sequence match</th>
<th>Web site of promoter sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIRC5</td>
<td>-298 to -294</td>
<td>aCCACGcc</td>
<td>1</td>
</tr>
<tr>
<td>BIRC5</td>
<td>-68 to -64</td>
<td>aCCACGgg</td>
<td>1</td>
</tr>
<tr>
<td>BIRC5</td>
<td>-56 to -52</td>
<td>gCCACGeg</td>
<td>1</td>
</tr>
<tr>
<td>RAB5C</td>
<td>-676 to -672</td>
<td>aCCACGtt</td>
<td>2</td>
</tr>
<tr>
<td>EIF2AK3/PERK</td>
<td>154 to 157</td>
<td>gaCGTGGc</td>
<td>3</td>
</tr>
<tr>
<td>HSPA5/BiP/GRP78</td>
<td>-8 to -4</td>
<td>tCCACGac</td>
<td>4</td>
</tr>
<tr>
<td>HSPA5/BiP/GRP78</td>
<td>-676 to -672</td>
<td>acCGTGGg</td>
<td>4</td>
</tr>
<tr>
<td>ATF6</td>
<td>-305 to -301</td>
<td>gCCACGct</td>
<td>5</td>
</tr>
<tr>
<td>ATF6</td>
<td>-853 to -849</td>
<td>tCCACGtg</td>
<td>5</td>
</tr>
<tr>
<td>ATF6</td>
<td>-850 to -846</td>
<td>caCGTGGt</td>
<td>5</td>
</tr>
<tr>
<td>HSPB8/H11</td>
<td>Not identified</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>GLO1</td>
<td>Not identified</td>
<td></td>
<td>7</td>
</tr>
</tbody>
</table>

1 – http://switchdb.switchgeargenomics.com/productinfo/id_721013/;
2 – http://switchdb.switchgeargenomics.com/productinfo/id_719552/;
3 – http://switchdb.switchgeargenomics.com/productinfo/id_705088/;
4 – http://switchdb.switchgeargenomics.com/productinfo/id_719178/;
5 – http://switchdb.switchgeargenomics.com/productinfo/id_711611/;
6 – http://switchdb.switchgeargenomics.com/productinfo/id_707887/;
7 – http://switchdb.switchgeargenomics.com/productinfo/id_718376/;

---

**Fig. 8.** Schematic representation of the effect of glutamine deprivation on the expression of genes encoding important proliferation related regulatory factors, such as ATF6, EIF2AK3/PERK, GLO1, BIRC5/survivin, RAB5C, HSPB8/H11, and HSPA5/BiP/GRP78, in the control and ERN1 knockdown glioma cells; NS – no significant changes.
and correlates with suppression of tumor cell proliferation [17, 46]. Our results concerning suppression of BIRC5 and RAB5C gene expressions in glioma cells after glutamine withdrawal completely agree with functional activity of proteins encoded by these genes as well as with biological significance of glutamine for glioma cells growth [15-17, 40-42, 45]. Furthermore, significant down-regulation of the expression level by glucose deprivation was shown for GLO1 gene, which has strong relation to the control of tumor growth [31-34]. Our results agree with data Hutschenreuther et al. [33] that glutamine withdrawal decreases GLO1. Recently was shown that the expression of GLO1 is increased in some cancers and plays a pro-tumor role, participates in epithelial-to-mesenchymal transition, transformation into a neoplastic-like phenotype [25, 34]. This enzyme metabolizes methylglyoxal, a cytotoxic metabolite, which induces the formation of advanced glycation of end-products and is increased in cancer [26]. It was also shown that knockdown of GLO1 in the cancer cells increases methylglyoxal level and significantly reduced tumor-associated properties such as migration and proliferation [26]. Therefore, our results concerning suppression of GLO1 gene expressions in glioma cells upon inhibition of ERN1 as well as upon glutamine withdrawal completely agree with functional role of this protein in tumor cells and with suppression of ERN1 knockdown glioma cell proliferation [7, 12, 22, 25, 26].

Therefore, the changes in expression level of genes encoding ATF6, EIF2AK3/PERK, GLO1, BIRC5/survivin, RAB5C, HSPB8, and HSPA5/GRP78 proteins possibly reflect metabolic reprogramming of glioma cells by glutamine deprivation as well as ERN1-mediated endoplasmic reticulum stress signaling and correlate with suppression of glioma cell proliferation upon inhibition of the ERN1 signaling enzyme.
IRE1 изменяет эффект дефицита глутамина на экспрессию факторов роста опухолей в клетках глиомы линии U87

О. Г. Минченко, А. П. Харькова, О. С. Гнатюк, О. Я. Лузина, И. В. Кривдюк, А. Ю. Кузнецова

Институт биохимии им. А. В. Палладина НАН Украины, Киев; e-mail: ominchenko@yahoo.com

В работе изучали экспрессию генов, кодирующих важные протеины, в клетках глиомы линии U87 при угнетении функции ERN1 (endoplasmic reticulum to nucleus signaling 1) и дефиците глутамина. Показано, что при дефиците глутамина снижался уровень экспрессии мРНК ATF6 (activating transcription factor 6), EIF2AK3/PERK (eukaryotic translation initiation factor 2 alpha kinase 3), GLO1 (glyoxalase I), BIRC5 (baculoviral IAP repeat-containing 5) и RAB5C (RAB5C, a member of RAS oncogene family) в контрольных клетках глиомы. В то же время, уровень экспрессии мРНК HSPB8 (heat shock 22 kDa protein 8) и HSPA5/GRP78 (heat shock protein family A (Hsp70) member 5) был резистентным к дефициту глутамина в этих клетках глиомы. Угнетение ERN1, модифицировало эффект дефицита глутамина на уровень экспрессии большинства изученных генов в клетках глиомы линии U87: увеличивало экспрессию генов ATF6 и HSPA5 и усиливало чувствительность генов EIF2AK3 и BIRC5 к дефициту глутамина. Более того, экспрессия исследуемых генов (за исключением EIF2AK3) снижалась в клетках глиомы при угнетении ERN1 в присутствии глутамина. Показано, что дефицит глутамина изменяет экспрессию большинства изученных генов в зависимости от ERN1 и эти изменения, возможно, причастны к угнетению роста глиом из клеток без функциональной активности сигнального энзима ERN1.

Ключевые слова: дефицит глутамина, угнетение ERN1, экспрессия мРНК, ATF6, EIF2AK3, BIRC5, RAB5C, HSPA5, клетки глиомы линии U87.

References


Received 19.03.2018